New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 4, 2014
08:00 EDTINCYIncyte ruxolitinib data 'a home run, ' says Oppenheimer
After Incyte reported results from a Phase III study of its ruxolitinib in polycythemia vera, Oppenheimer expects the drug to be approved and generate significant commercial sales. The firm keeps a $75 price target and Outperform rating on the stock.
News For INCY From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
October 31, 2014
10:00 EDTINCYOn The Fly: Analyst Upgrade Summary
Subscribe for More Information
October 30, 2014
18:41 EDTINCYIncyte upgraded to Neutral from Sell at Goldman
Subscribe for More Information
13:35 EDTINCYIncyte price target raised to $80 from $69 at Piper Jaffray
Piper Jaffray raised its price target for Incyte shares to $80 saying Jakafi demand was strong in Q3. Piper keeps an Overweight rating on the stock.
07:11 EDTINCYIncyte reports Q3 EPS 33c, may not compare to consensus 0c
Reports Q3 revenue $198.15M, consensus $149.92M. The Company now expects that 2014 net product revenues from Jakafi will be in the range of $350 million to $360 million, an increase from the previous range of $330 million to $340 million.
October 21, 2014
07:54 EDTINCYLeerink a buyer of Alkermes, ImmunoGen, Incyte
Subscribe for More Information
October 17, 2014
08:01 EDTINCYIncyte names Gryska CFO to succeed Hastings
Incyte announced the appointment of David Gryska as Executive Vice President and CFO, effective October 31. Gryska will succeed David Hastings, who has served as Incyte’s Executive Vice President and CFO since October 2003. Hastings, who is leaving the company to pursue other opportunities, will remain with Incyte through the end of November and will work closely with Gryska to ensure a seamless transition.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use